Dario Callegaro, MD (he/him/his)

Surgical Oncologist
Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

I am a surgical oncologist working at Istituto Nazionale Tumori, Milan, Italy. I did the university and general surgery residency training in Milan before completing a Surgical Oncology fellowship at University of Toronto in 2020.
My practice is fully dedicated to the care of patients with soft tissue sarcoma and gastrointestinal stromal tumor. I have been practicing in the Sarcoma Service at Istituto Nazionale Tumori, Milan, Italy, since 2017. This is one of the major sarcoma referral center in Europe. My main research focus is on the development and integration into practice of prognostic models for patients with soft tissue sarcoma of the extremity and of the retroperitoneum. I am author of one of the few available app for smartphone and tablet for predicting prognosis of patients with soft tissue sarcoma: Sarculator. I enjoyed being part of, contribute to and learn from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group since its very beginning. Within the group I am now coordinating the Education Committee and the 2021-2022 Educational Webinar Series (https://tarpswg.org/webinars).

Poster(s):

• (P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL

• (P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY

• (P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL

• (P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)

• (P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP

• (P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?